Saturday 17 October 2026
Export BCDA’s income statement to Excel — free account
BioCardia, Inc.
BCDA Healthcare Biotechnology
BioCardia, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $477,000.00, up 722.4% from fiscal 2024. In the quarter to June 2026, EPS grew 67.5% and free cash flow fell 5.15%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
0.92
0.02
−2.13%
Follow BCDA
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
3 | 3 | 4 | 4 | 5 | 5 | 3 | 2 | 3 | 4 |
Altman Z-Score |
39.58 | 12.80 | (14.78) | 15.56 | (3.23) | (9.62) | (18.91) | (83.06) | (65.93) | (74.83) |
P/S ratio |
186.58 | 221.58 | 73.72 | 29.27 | 241.57 | 32.35 | 28.46 | 29.31 | 13.98 | 19.47 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
9.30 | (13.44) | (53.37) | 33.98 | (10.71) | (25.98) | (51.06) | (197.36) | (153.77) | (176.15) |
P/Operating CF |
(42.73) | (42.03) | (14.19) | (6.38) | (10.25) | (11.04) | (12.84) | (7.55) | (2.46) | (3.34) |
Beneish M-Score |
— | — | (5.04) | 0.11 | 20.41 | 2.96 | (2.80) | (6.09) | — | — |
P/B ratio |
5.22 | 9.54 | 12.15 | 8.77 | 1.83 | 3.17 | 7.86 | 0.00 | 7.15 | 9.31 |
Price to Tangible BV |
5.22 | 9.54 | 12.15 | 8.77 | 1.83 | 3.17 | 7.86 | 0.00 | 7.15 | 9.31 |
EV/Sales |
159.36 | 206.93 | 74.22 | 30.26 | 134.60 | 25.48 | 27.37 | 39.36 | 22.21 | 27.42 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(16.62) | (11.43) | (4.19) | (2.27) | (1.58) | (2.49) | (3.50) | (1.88) | (1.21) | (1.58) |
EV/FCF |
(16.01) | (11.25) | (4.17) | (2.24) | (1.58) | (2.47) | (3.48) | (1.88) | (1.20) | (1.58) |
Quick Ratio |
14.84 | 5.48 | 2.21 | 1.43 | 5.24 | 3.51 | 2.11 | 0.32 | 1.02 | 1.03 |
Current Ratio |
15.18 | 5.71 | 2.44 | 1.59 | 5.33 | 3.63 | 2.19 | 0.40 | 1.13 | 1.12 |
Net Debt/EBITDA |
2.82 | 1.03 | 0.38 | 0.40 | 1.38 | 1.02 | 0.62 | 0.10 | 0.30 | 0.30 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.04 | 0.03 | 0.06 | 0.10 | 0.01 | 0.05 | 0.11 | 0.07 | 0.02 | 0.13 |
Operating CF/Net income |
0.54 | 0.70 | 0.79 | 0.64 | 0.82 | 0.82 | 0.89 | 0.86 | 0.99 | 0.90 |
Capex/Depreciation |
0.00 | (1.74) | (0.75) | (1.32) | (0.47) | (1.93) | (0.85) | (0.14) | (0.09) | (0.29) |
Interest Coverage |
(4.38) | (130.58) | (119.51) | (126.90) | (5,176.33) | (1,403.33) | — | — | — | — |
| 71.37% | (77.64%) | (187.53%) | (477.41%) | (139.27%) | (85.43%) | (155.98%) | (703.62%) | 2,074.67% | (950.12%) | |
| (76.53%) | (69.11%) | (140.19%) | (208.71%) | (96.48%) | (64.50%) | (93.35%) | (181.08%) | (236.81%) | (230.57%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(50.09%) | (110.37%) | (366.63%) | (575.47%) | (80.86%) | (126.85%) | (267.63%) | 563.61% | (2,379.04%) | (2,603.80%) |
Average Days of Receivables |
46.89 | 72.39 | 160.02 | 75.57 | 2,139.66 | 52.86 | 54.26 | 48.21 | 0.00 | 15.30 |
Research and Development Expense of Revenue |
578.13% | 1,210.65% | 1,352.48% | 1,205.92% | 6,764.83% | 843.15% | 653.40% | 1,619.71% | 7,563.79% | 1,040.25% |
Selling, General and Administrative Expense of Revenue |
713.19% | 1,335.07% | 921.12% | 845.49% | 4,042.07% | 501.18% | 326.85% | 921.38% | 6,331.03% | 695.18% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
163.54% | 565.14% | 443.84% | 383.38% | 2,035.86% | 163.65% | 87.50% | 215.93% | 1,277.59% | 90.15% |
Graham Net Nets |
0.19 | 0.10 | 0.08 | 0.05 | 0.53 | 0.25 | 0.08 | (0.22) | (0.04) | 0.03 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.51 | 0.00 | 0.00 |
Earnings Yield |
(9.59%) | (11.60%) | (30.36%) | (75.31%) | (45.93%) | (38.64%) | (30.40%) | (83.29%) | (141.71%) | (103.20%) |
Free Cash Flow Yield |
(5.33%) | (8.30%) | (24.17%) | (46.15%) | (35.37%) | (31.92%) | (27.63%) | (71.44%) | (131.94%) | (89.32%) |
Revenue per Share |
9.29 | 1.69 | 2.20 | 1.89 | 0.21 | 0.90 | 1.14 | 0.34 | 0.02 | 0.07 |
Operating CF per Share |
(89.06) | (30.66) | (38.92) | (25.09) | (18.31) | (9.19) | (8.93) | (7.06) | (2.87) | (1.12) |
Capex per Share |
0.00 | (0.48) | (0.23) | (0.39) | (0.05) | (0.10) | (0.06) | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
(89.06) | (31.14) | (39.15) | (25.47) | (18.36) | (9.29) | (8.99) | (7.07) | (2.88) | (1.12) |
Cash per Share |
344.39 | 44.87 | 18.84 | 14.83 | 31.72 | 11.41 | 6.23 | 0.78 | 0.86 | 0.37 |
Shareholders Equity per Share |
331.97 | 39.34 | 13.33 | 6.29 | 28.41 | 9.19 | 4.14 | (1.14) | 0.31 | 0.13 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
331.97 | 39.34 | 13.33 | 6.29 | 28.41 | 9.19 | 4.14 | (1.14) | 0.31 | 0.13 |
Free Cash Flow |
(5.52) | (8.81) | (11.13) | (9.59) | (12.39) | (10.48) | (10.63) | (9.99) | (7.89) | (7.44) |
Working Capital |
20.47 | 10.98 | 3.67 | 2.38 | 18.41 | 9.77 | 4.28 | (2.15) | 0.30 | 0.30 |
Capital Expenditures |
— | (0.14) | (0.07) | (0.15) | (0.03) | (0.12) | (0.07) | (0.01) | (0.01) | (0.01) |
Net Current Asset Value |
20.42 | 10.90 | 3.59 | 1.07 | 18.41 | 8.14 | 2.96 | (3.13) | (0.26) | 0.21 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.28 | 0.11 | 0.21 | 0.22 | 0.11 | 0.05 | 0.03 | 0.10 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.35 | 0.46 | 0.61 | 0.61 | 0.47 | 0.33 | 0.48 | 0.89 | 2.03 | 1.50 |
Cash ROIC |
(13.17%) | (36.98%) | (121.69%) | (120.57%) | (30.53%) | (45.09%) | (86.75%) | 1,997.20% | (246.01%) | (219.49%) |
Accounts Receivable Turnover |
6.36 | 5.67 | 3.39 | 3.37 | 0.29 | 2.04 | 7.77 | 3.61 | 0.00 | 11.49 |
Accounts Payable Turnover |
1.40 | 0.97 | 0.63 | 0.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
1.67 | 4.23 | 3.11 | 4.94 | 1.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
256.87 | 477.14 | 524.56 | 931.87 | 68,072.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
66.05 | 101.04 | 99.55 | 4.08 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.09 | 0.08 | 0.18 | 0.21 | 0.50 | 0.50 | 0.17 | 0.13 | — | 0.04 |
Average Payables |
0.53 | 0.71 | 0.82 | 0.83 | 0.83 | 0.63 | 0.60 | 0.79 | 0.64 | 0.51 |
Average Inventory |
0.45 | 0.16 | 0.17 | 0.07 | 0.00 | — | — | — | — | — |
Average Assets |
13.47 | 17.81 | 9.98 | 7.05 | 15.55 | 19.57 | 12.76 | 6.39 | 3.36 | 3.57 |
Average Common Equity |
(14.44) | 15.85 | 7.46 | 3.08 | 10.77 | 14.78 | 7.63 | 1.64 | (0.38) | 0.87 |
Columns are period end dates